CytoSorbents to Report Fiscal 2013 Operating and Financial Results

      CytoSorbents to Report Fiscal 2013 Operating and Financial Results

PR Newswire

MONMOUTH JUNCTION, N.J., March 25, 2014

MONMOUTH JUNCTION, N.J., March 25, 2014 /PRNewswire/ --CytoSorbents
Corporation (OTCQB: CTSO), a critical care immunotherapy company
commercializing its European Union approved CytoSorb® blood filter to treat
life-threatening illnesses in the intensive care unit, will report fiscal 2013
financial results after the market close on Monday, March 31, 2014.

CytoSorbents' management will host a live conference call and presentation
webcast that will recount both operational and financial progress during Q4
2013 and fiscal year ending December 31, 2013, and answer pre-submitted
questions as time permits.

Conference Call Details:
Date: Monday,March 31, 2014
Time: 4:15 PM Eastern
Participant Dial-In: (480) 629-9760
Live Presentation Webcast:

It is recommended that participants dial in approximately 10 minutes prior to
the start of the call. There will also be a simultaneous live webcast of the
conference call that can be accessed through the following audio feed link:

An archived recording of the conference call will be available under the
Investor Relations section of the Company's website at

Investors are encouraged to submit their questions in advance as soon as
possible to Ms. Amy Vogel at

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company
using blood purification to control severe inflammation -- with the goal of
preventing or treating multiple organ failure in life-threatening illnesses.
Organ failure is the cause of nearly half of all deaths in the intensive care
unit, with little to improve clinical outcome. CytoSorb®, the Company's
flagship product, is approved in the European Union as a safe and effective
extracorporeal cytokine filter, designed to reduce the "cytokine storm" that
could otherwise cause massive inflammation, organ failure and death in common
critical illnesses such as sepsis, burn injury, trauma, lung injury, and
pancreatitis. These are conditions where the risk of death is extremely high,
yet no effective treatments exist. CytoSorbents' purification technologies are
based on biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture and
surface adsorption. CytoSorbents has numerous products under development based
upon this unique blood purification technology, protected by 32 issued US
patents and multiple applications pending, including HemoDefend™,
ContrastSorb, DrugSorb, and others. Additional information is available for
download on the Company's website:

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. Risk factors are detailed
in the Company's Form 10-K filed with the SEC on April 3, 2013, which is
available at

Please Click to Follow us on Facebook and Twitter

SOURCE CytoSorbents Corporation

Contact: CytoSorbents Corporation: Dr. Phillip Chan, MD, PhD, Chief Executive
Officer, (732) 329-8885 ext. *823, or Investor Contact:
Amy Vogel, (732) 329-8885 ext. *825,
Press spacebar to pause and continue. Press esc to stop.